Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 32

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 32
---
 ratifying any transaction required to be reported under Items 404(a) and 404(d) of Regulation S-K. In reviewing related person transactions, the Audit Committee evaluates any transaction in which the Company was or is to be a participant and the amount involved exceeds $120,000, since the beginning of the Company's last fiscal year, and in which the “related person” (as defined in Item 404(a) of Regulation S-K) had, or will have, a direct or indirect material interest. The Audit Committee also will consider whether the proposed terms are at least as favorable to the Company as could be obtained from unaffiliated third parties and will confirm that there is a bona fide business purpose for the transaction. There were no related person transactions since January 1, 2024 that require disclosure under Item 404 of Regulation S-K.

23

EXECUTIVE COMPENSATION Compensation Discussion and Analysis The following information describes the material elements of 2024 compensation awarded to, earned by, or paid to each of the following executive officers, who are referred to collectively as our “ Named Executive Officers ”: Craig Collard, Chief Executive Officer ; Ira Duarte, Executive Vice President, Chief Financial Officer ; and Dr. William Forbes, Executive Vice President, Chief Development Officer Executive Summary Our Named Executive Officer compensation program is thoughtfully designed to attract, motivate and retain high-caliber executives who drive our success, to promote teamwork in a straightforward and effective way, and to emphasize the executives’ shared responsibility for our overall success. We structure our Named Executive Officer compensation program to include significant performance metrics that are aligned with our business strategy and shareholder value creation. Listed below are highlights of our fiscal 2024 Named Executive Officer compensation policies and practices:

| WHAT WE DO |                                                                                                                                        |
| ✓          | Performance-based cash and equity incentive compensation                                                                               |
| ✓          | Caps on performance-based cash and equity incentive compensation                                                                       |
| ✓          | Significant portion of Named Executive Officer compensation at risk based on company performance                                       |
| ✓          | Multi-year equity award vesting periods for equity awards, including four-year performance periods for performance-based equity awards |
| ✓          | One-year minimum vesting requirement under equity incentive plan, with limited exceptions                                              |
| ✓          | Annual review and approval of our Named Executive Officer compensation program                                                         |
| ✓          | Annual compensation risk assessment                                                                                                    |
| ✓          | Annual “Say On Pay” vote                                                                                                               |
| ✓          | Clawback policy on certain cash and equity incentive compensation                                                                      |